reason report
blood diseas pure initi op pt
bottom line initi coverag imara inc
imra outperform rate price target
month imra clinical-stag biopharmaceut compani focus
develop commerci novel therapeut treat
hemoglobinopathi believ rare blood disord pure play could
garner greater investor interest patient-friendli oral select
inhibitor advanc
potenti disease-modifi therapi current develop
sickl cell diseas scd -thalassemia rare hemoglobinopathi
approv treatment option signific unmet medic
need pend continu posit data pois potenti
re-defin standard care soc scd becom first
approv oral treatment -thalassemia two studi
initi look forward string potenti de-risk
value-cr catalyst imra next two year
multimod mechan action moa may
differenti hemoglobinopathi therapi market
develop highli select inhibitor
inhibit increas cyclic gmp cgmp level action
associ reactiv fetal hemoglobin hbf red blood cell
rbc reduct blood cell adhes reduct white blood
cell activ demonstr improv
symptom lower diseas burden scd -thalassemia
believ could multipl advantag therapi
includ rapid onset hbf induct multimod moa daili oral
administr favor toler profil drug product stabil
note shelf stabl high temperatur humid
could facilit world-wide access includ underserv region
scd -thalassemia preval
patient-friendli oral potenti lack
liabil monitor side effect hydroxyurea could re-
defin soc scd scd pt demonstr statist
signific increas hbf rbc f-cell notabl increas
hbf without sign neutropenia tachycardia hypotens
hydroxyurea current soc often result unwant side effect
toxic risk therapeut dose level safe efficaci
could becom prefer oral treatment pt scd
top-line data studi expect imra track
launch ardent studi random placebo-
control studi assess higher dose longer treatment
durat addit clinic endpoint compani trial
ardent interim result expect
dcf discount rate
net debt total capit
year price history/av daili volume mil imra
compani inform svb leerink llc research
accord gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
current approv oral medic could
becom first small molecul market -thalassemia
although distinct diseas scd -thalassemia share similar
aspect pathophysiolog symptomolog thu
also develop non-transfus depend ntd
induc signific improv function hemoglobin total
count erythroblast matur fort studi
slate initi could de-risk -thalassemia
interim result expect
blood diseas pure initi op pt
hemoglobinopathi
imara inc imra clinical-stag biopharmaceut compani focus develop
commerci novel therapeut treat hemoglobinopathi pend posit data initi
product candid potenti disease-modifi oral treatment sickl cell diseas
scd -thalassemia rare blood disord approv treatment option signific
unmet medic need although distinct diseas scd -thalassemia share similar pathophysiolog
symptomolog highli select inhibitor
inhibit increas cyclic guanosin monophosph cgmp level associ
reactiv fetal hemoglobin hbf red blood cell rbc reduct blood cell adhes
lower white blood cell activ demonstr improv symptom
lower diseas burden scd -thalassemia potenti multimod moa differenti
oral hemoglobinopathi therapi develop scd patient
demonstr statist signific increas hbf rbc f-cell notabl increas hbf
without sign neutropenia tachycardia hypotens hydroxyurea current standard
care often result unwant side effect toxic risk therapeut dose level safe
efficaci could becom prefer oral treatment patient scd top-line data
phase studi expect imra plan launch phase random placebo-
control studi scd patient beyond scd pursu non-transfus
depend ntd transfus depend td -thalassemia current approv oral
medic could becom first small molecul market -thalassemia phase
studi slate initi could de-risk -thalassemia two
studi initi look forward string value-cr catalyst imra
garner increas investor interest hemoglobinopathy-focus compani
deriv one-year pt imra base dcf
analysi use discount rate termin
current ascrib valu compani two
hemoglobinopathi program sickl cell diseas scd
 scd assign us/eu probabl
success po project peak sale
 -thalassemia assign us/eu po
project peak sale
imra risk valuat
clinical-stag compani risk imra includ clinic regulatori financi
 lead asset add signific binari risk head data readout
 full safeti profil includ long-term use remain unknown
 clinic risk includ unexpectedli posit data competitor
 commerci uptak sale
imara inc imra clinical-stag biopharmaceut compani focus develop
commerci novel therapeut treat hemoglobinopathi
initi product candid potenti disease-modifi oral treatment sickl cell diseas scd
sub-optim agent scd approv oral therapi -thalassemia signific unmet medic need
hemoglobinopathi
back high qualiti investor imra capabl manag team view keenli focus advanc rare blood
ipo allow extend cash runway estim fund oper multipl value-cr
imra initi late-stag trial lead candid
bull vs bear argument imara
pure play hemoglobinopathi compani offer focu
imra heavili depend success sole
biotech area wide investor interest
patient-friendli oral -- potenti lack
liabil monitor side effect
hydroxyurea could re-defin soc scd
propos benefit inhibit may fail
materi diseas modifi treatment
pend posit data could becom first
remain seen higher dose
oral therapeut option -thalassemia pt
lead improv efficaci
peripher activ highli select could
although well-toler date small number
deliv promis previous unfulfil
recent success
highli valu hemoglobinopathi compani lead
compound demonstr limit clinic benefit
imra exclus world-wide licens allow
access larg scd -thalassemia
market us eu asia beyond
patient long-term safeti remain unknown
new clinic trial endpoint chang fetal
hemoglobin although appear time dose
depend present signific unknown path
crowd competit landscap potenti
cur gene therapi daili oral may result
commerci product ahead
success
hemoglobinopathi rare inherit genet disord
abnorm product absenc hemoglobin
mutat gene encod hemoglobin
structur abnorm hemoglobin
block blood flow organ
lead vaso-occlus crisi voc
acut pain episod result obstruct
decreas absent product
inadequ deliveri oxygen tissu
scd character debilit pain
-thalassemia caus sever anemia
estim us eu
estim us eu combin
imra potenti serv broad rang
measur rapid induct cgmp across
inhibitor bayri
differenti select highli specif
select pde famili member
potenti minim off-target effect
select pfe analog
benefit long-term use adult children
unlik hydroxyurea hu current soc scd
induc neutropenia
teratogen impact fertil reproduct
low brain penetr rel inhibitor
preclin model suggest limit impact
develop function brain exposur level
lower pfe analog
drug product stabil stabl high
temperatur humid potenti allow
world-wide access includ underserv region
scd -thalassemia endem
imara compani present file svb leerink research
level associ
reactiv fetal hemoglobin hbf red
blood cell rbc reduct blood cell
adhes lower white blood cell
activ gave
demonstr improv symptomolog
lower diseas burden scd -thalassemia
project peak revenu opportun scd
patient diagnos seek treatment us scd potenti disease-modifi oral
medic lack side effect drawback current soc could see signific commerci uptak
cheap effect standard care soc side effect concern soc hydroxyurea hu
effect howev scd patient respond hu non-compli hu treatment
model monotherapi well hu-combin therapi scd ddi observ
project conserv commerci uptak peak penetr mani
development program target scd sever angl small molecul hbf induc anti-adhes biolog
gene therapi etc success competitor commerci launch remain unknown
price assumpt us/eu competit yearli cost
scd oral medic endari emma clock per year oxbryta per year
once-a-day oral therapi potenti disrupt scd market
highli select potent small molecul inhibitor
oral once-a-day potenti disease-modifi treatment scd -thalassemia
trial fulli enrol on-going top-line result expect
patent protect
mechan
scd nitric-oxid -cgmp pathway dysregul lead reduct cgmp
cgmp level lead reduc blood flow increas inflamm greater cell adhes
activ hydrolyz cgmp gmp thu inhibit robustli increas cgmp
multimod moa act primarili rbc potenti act wbc adhes mediat
 cell type implic scd
date hydroxyurea hu l-glutamin emma endari gbt anti-sickl agent oxbryta
nvss anti-p-selectin adakveo approv treatment scd
standard
blood transfus may also requir acut increas normal rbc
hematopoiet stem cell transplant potenti cur obstacl widespread use includ
lack suitabl donor concern immunolog transplant reject long term-advers event
stand us
organ
modul ischemia-reperfus injuri oxid stress
current approv nearest competitor develop show signific drawback
although gold standard treatment scd hydroxyurea hu reduc pt reach due safeti concern escal dose regim
extens monitor variabl respons rate potenti advers effect fertil long-term carcinogen potenti
hematopoiet stem cell transplant potenti cur obstacl widespread use includ lack suitabl donor concern
immunolog transplant reject risk long term-advers event
gene therapi earli develop may suitabl and/or feasibl scd pt
gbt oxbryta demonstr increas hemoglobin fail significantli reduc voc frequenc altern nv iv-
administ adakveo shown reduc voc treat underli caus diseas
imping similar biolog pathway soc hydroxyurea set
potenti benchmark
hu signific drawback
hydroxyurea chemotherapeut agent pleiotrop
although benefit consider hu reduc
effect includ increas fetal hemoglobin rbc
reduc adhes wbc vascular endothelium
patient reach due
 continu safeti monitor due hu
hu shown significantli decreas vaso-
myelosuppress properti risk neutropenia
occlus crise voc also increas hbf
genet studi shown scd patient
higher level hbf associ milder clinic
hu propos mediat hbf induct
stimul solubl guanyl cyclas increas cgmp
provid altern pathway increas cgmp
level inhibit
hu increas cgmp hu also
impact pathway dna replic thu
may confer efficient/effect therapeut
 black box warn hematotox reproduct
toxic teratogen genotox cutan tox
thu despit signific clinic improv
scd pt hu underutil under-dos
us patient discontinu use within
month leav signific portion
imra abl demonstr clinic signific chang hbf
safe well toler manner pois re-defin soc scd
base prior studi fda agre hbf threshold
like accept endpoint could potenti use
acceler approv scd
publish literatur demonstr even small increas hbf lead substanti risk reduct
clinic outcom scd pt includ mortal stroke pain blood transfus
therefor hbf could serv potenti surrog endpoint acceler approv scd
type meet imra fda set potenti threshold baselin accept endpoint
fda like take holist view imra data includ hbf biomark vaso-
occlus crise voc patient-report outcom qualiti life qol data determin
could provid meaning clinic benefit scd pt
amend phase data expect could add clinic
support develop scd
sub-studi assess
dose mg mg
week escal
higher dose mg
mg respect week
imra amend trial protocol
acceler dose escal
allow pt higher dose
month prior
elimin mg dose
group follow amend
addl pt dose
studi assess
initi dose mg top
stabl dose hu escal
mg dose
trial protocol extend dose
addit month follow
amend addl pt
dose
still track despit
pandem imra plan report safeti
toler pk/pd efficaci data
includ chang hbf
interim analysi data demonstr safeti
toler well posit trend efficaci measur
scd pt gener safe well toler month
 evid neutropenia common side effect hu treatment
earli evid efficaci
trend reduc cell adhes
biomark sp-selectin svcam
well inflammatori marker
myeloperoxidas mpo compar
week increas
f-cell rbc detect level
fetal hemoglobin pair trend toward
increas hemoglobin
week decreas reticulocyt
patient report improv pain
also observ
interim analysi data demonstr statist
signific increas f-cell absolut increas hbf
increas f-cell
increas hbf
fda set
threshold
increas f-cell believ preced chang
hbf express
sig increas f-cell week
repres mean increas baselin
absolut chang hbf establish
correl improv clinic outcom
increas hbf week
repres mean increas baselin
soc hu shown increas f-cell year
soc hu demonstr increas hbf year
earli efficaci measur place par hu without unwant side effect
studi evalu higher dose longer treatment period addit clinic
furthermor interim data illustr smaller proport pt
report voc increas dose
monotherapi combin popul percent patient report vaso-occlus crise
voc decreas dose-depend manner studi power show
differ voc pt number small direction result promis view
safeti toler
higher dose group mild mostli gi-rel
sae voc event determin relat
mild mostli gi-rel
underli diseas evenli distribut across dose
sae disease-rel voc event
reduct neutrophil monocyt count
reduct neutrophil monocyt count
tachycardia hypotens report
tachycardia hypotens report
dose higher titrat ardent
scd slate initi
stratifi hu use
primari endpoint wk
initi
primari endpoint week
proport pt hbf respons
defin increas hbf baselin week
trial power detect delta arm
incid voc
week
vaso-occlus crise voc relat hbf level
qualiti life qol measur
pt reach week
higher weight-bas dose upcom studi anticip
improv efficaci sever unknown remain
unlik imra studi examin increas dose util weight-bas dose
elimin dose titrat due possibl wide rang pt weight management believ weight-bas dose
precis manag drug exposur toler studi assess dose
studi lower-dos arm test rang includ
dose higher-dos arm test includ dose
independ dmc review lower-dos safeti toler data imra proce
higher dose
predict exposur dose surpass mean exposur
maximum toler dose ph mad trial still lower establish dog noael
remain seen higher dose studi lead clinic meaning increas
hbf hit fda bar without safeti toler issu
gbt studi oxbryta may provid roadmap imra
studi scd
patient treat
mg oxbryta formerli
increas total
hemoglobin
patient level
assess chang total hemoglobin
hb imra plan examin chang
hbf novel endpoint scd
trial hbf induct clearli
link meaning clinic outcom
degre chang hbf
requir elicit clinic improv
fda set hbf threshold
success expect
endpoint requir remain
unknown add signific risk
outperform hu across key measur preclin studi scd
model suggest multimod moa
induc hbf reduc sickl rbc
line scd
key aspect
project peak revenu opportun
thalassemia
approv oral therapi us -thalassemia could first oral medic market
potenti offer conveni option transfus non-transfus depend patient
us offer small meaning market howev eu patient popul larger highest carrier
frequenc world-wide report cypru sardinia -thalassemia prevent mediterranean countri
north america offer signific market opportun eu
project conserv commerci uptak peak penetr potenti cur
therapi includ hematopoiet stem cell transplant hsct gene therapi zynteglo may
captur market high price tag long-term safeti uncertainti risk may appeal
thalassemia patient furthermor multipl small molecul peptid biolog develop commerci
success competitor remain uncertain junctur
price assumpt us/eu quit competit yearli cost
transfus therapi averag per year
current approv oral therapi -thalassemia
standard
current approv oral therapi
thalassemia us
newli approv xlrn reblozyl
erythroid matur agent shown
reduc transfus burden dose
soc mani frequent blood transfus
manag anemia long-term transfus
therapi use maintain patient
hemoglobin level g/dl
chronic blood transfus effect
manag symptom lead iron overload
time caus mortal due iron-
associ heart liver toxic
overload often address iron
chelat pain
hematopoiet stem cell transplant
potenti cur obstacl widespread
use includ lack suitabl donor concern
immunolog transplant reject long term-
although distinct diseas scd -thalassemia
share similar pathophysiolog symptomolog
oral therapi develop pend
patient-friendli oral address key biolog
condit market author eu
preclin work -thalassemia set stage studi
recal -thalassemia caus mutat beta globin gene result less hemoglobin fewer red
blood cell mous model ntdt induc stat sig increas function hemoglobin
ineffect erythropoiesi anoth key featur -thalassemia promot matur mechan
reduc patholog day daili administr erythroblast matur significantli
improv demonstr increas matur erythroblast comparison immatur erythroblast
fort -thalassemia slate initi
endpoint td pt
reduct
compar week
prior screen
improv iron
endpoint ntd pt
chang total
placebo
chang fetal
improv anemia
initi
pt reach week
expect
season manag team focus execut rare diseas pipelin
busi develop broad institut harvard/mit
phd biochemistri georgetown univers ms john hopkin ba brown kauffman fellow
year pharma experi led multipl trial
execut director clinician group lead pfizer diseas
director wyeth research clinic research physician
md vrije universiteit medic school amsterdam netherland
presid ceo cfo arsani asn
cfo cbo curi cri
mba babson colleg bs busi administr bryant colleg member aicpa abfo
kevin johnson ph senior vice-president regulatori qualiti
vice presid global head regulatori qualiti sucampo
vice presid global regulatori affair vtess
director global regulatori affair diseas gene therapi glaxosmithklin
phd neurobiolog univers north carolina chapel hill kenan-flagl school busi
imara hold world-wide exclus right treatment
licens lundbeck a/
 world-wide exclus patent right inhibitor area except
composit matter patent famili
set expir
 method use
therapi hemoglobinopathi
pend posit data may offer daili oral safe replac adjuv
hydroxyurea hu scd first oral therapeut option -thalassemia patient
posit interim data phase trial bode well efficaci scd
upcom phase studi non-transfus depend transfus depend -thalassemia
offer potenti de-risk second indic
pure play hemoglobinopathi compani offer focu biotech area wide investor interest
season manag team back high qualiti investor
recent ipo allow suffici cash runway estim fund oper
multipl value-cr catalyst
imra track initi late-stag trial lead candid
anticip market entri
preced
file
approv
scd us
base
endpoint
hbf
voc
requir
full us
project peak revenu opportun scd
royalti imra eu
royalti rate hluyi
royalti payment hluyi
royalti lundbeck a/
royalti eu partner
probabl success po us
probabl success po eu
project peak revenu opportun
thalassemia
treat
treat
royalti imra eu
royalti rate hluyi
royalti payment hluyi
royalti lundbeck a/
royalti eu partner
probabl success po us
probabl success po eu
reawaken fetal hemoglobin offer potenti therapeut approach
-globin disord
hemoglobin hb tetram
consist
alpha-globin
beta-lik globin
-like globin gene
encod singl stretch
dna linearli arrang
chromosom
order express
shown
critic regul -globin cluster
determin when/which form
hb express fetal
highly-express form hb
birth adulthood
lower oxygen affin hbf
subunit mutat scd
globin express
-like globin gene strict
development control lcr
subunit mutat scd
bauer et al blood angastinioti et al prevent thalassemia haemoglobin disord
pathobiolog process scd
adhes
endothelium
equival
chang cash usd mm
